A Nutraceutical-Based Approach to the Management of Inflammatory Bowel Disease (IBD): A Protocol Proposal for Symptom Modulation and Gut-Lining Support

<b>Background &amp; Rationale</b> Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract and disruption of the intestinal mucosal barrier. Current pharmacological treatments often involve immunosuppressants or corticosteroids, which carry potential long-term side effects. There is growing interest in complementary, non-pharmaceutical strategies to support mucosal healing, reduce inflammation, and restore nutritional balance. This proposal originates from personal clinical experience and observation as a hypothesized “patient zero” for a novel, IBD-related inflammatory presentation. Based on that case, a nutraceutical protocol was designed to explore the synergistic benefits of accessible, well-tolerated supplements for IBD symptom modulation. <b>Objective</b> To evaluate the safety and potential effectiveness of a combination nutraceutical protocol in reducing gastrointestinal inflammation, supporting mucosal integrity, and improving overall symptom control in individuals with IBD. <b>Proposed Intervention</b> The protocol includes the following over-the-counter agents, selected for their established anti-inflammatory, antioxidant, and gut-healing properties: - Quercetin – A flavonoid with known zinc ionophore activity; modulates immune response and intestinal permeability - Bromelain – A proteolytic enzyme with anti-inflammatory and tissue-repair properties - Zinc acetate – An essential trace element important for epithelial repair and immune function - Vitamin C – Antioxidant support and collagen synthesis for gut-lining regeneration - Vitamin D – Immune modulation and maintenance of intestinal barrier function <b>Hypothesis</b> The combination of quercetin, bromelain, zinc, vitamin C, and vitamin D may synergistically: - Decrease mucosal inflammation - Promote epithelial healing and barrier function - Improve micronutrient status in IBD patients - Reduce symptom burden and enhance quality of life <b>Methodology (Phase I Concept)</b> Study Design: Observational case series followed by a prospective open-label pilot Sample Size (initial): 5–10 participants with mild-to-moderate IBD symptoms Inclusion Criteria: Diagnosed IBD, not on biologics or willing to pause during supplementation under physician supervision <b>Outcome Measures:</b> - Clinical symptom scores (e.g., SCCAI, CDAI) - Fecal calprotectin and CRP levels - Quality of life (IBD-Q) - Safety/tolerability and adverse event tracking <b>Expected Outcomes</b> This preliminary investigation aims to establish safety, patient compliance, and potential symptom improvements, with the goal of informing a larger randomized controlled trial in the future. <b>Significance</b> If successful, this protocol may offer a low-cost, accessible adjunct therapy for individuals with IBD, reduce dependency on long-term immunosuppressants, and contribute to the growing field of integrative gastroenterology. <b>Appendix</b> - Full ingredient protocol (with dosing schedule) - Literature review supporting each component - Draft patient intake and outcome tracking forms